CAR-T Cell Therapy for Early-Stage Type 1 Diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to stop the body's immune system from attacking insulin-producing cells in type 1 diabetes. The goal is to help preserve remaining pancreas function in people with early-stage disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–40 years old
- Diagnosed with stage 2 or stage 3 type 1 diabetes (early to intermediate stages, not long-standing disease)
- Blood tests show at least one diabetes-related autoantibody (immune marker), with two or more preferred
- Pancreas still producing some insulin (shown by C-peptide test results above certain thresholds)
- No other types of diabetes, severe organ disease, active infections, or uncontrolled blood sugar crises
- Willing to use reliable birth control for 1 year if able to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment made from stem cells that may help people with diabetes who have dangerous low blood sugar episodes. It aims to see if these cells can replace some of the pancreas function and prevent severe hypoglycemia.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
This study tests a new immune therapy using your own modified cells to try to stop type 1 diabetes from getting worse. It is for young adults who were recently diagnosed and still make some insulin.
This trial tests a new combination treatment for children who have been diagnosed with stage 1 type 1 diabetes, meaning they have some markers but do not yet need insulin. The treatment uses special immune cells (Treg cells) and an antibody (anti-CD20) to try to preserve the body's ability to make insulin.
This trial tests a new one-time treatment called CARC-101C for people recently diagnosed with type 1 diabetes. It aims to see if this treatment can help preserve the body's ability to make insulin and improve blood sugar control.
This trial tests whether giving your own regulatory T cells (a type of immune cell) back to you can help slow or stop the immune attack on your pancreas in type 1 diabetes. It is for people aged 8 to 65 who still make some insulin.
Hear when a new T1DM - Type 1 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.